The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | CANDOR results reveal new regimen for RRMM: KdD
Saad Usmani, MD, FACP, University of North Carolina School of Medicine, Chapel Hill, NC, presents the results from the primary analysis of CANDOR (NCT03158688), a multicenter, phase 3, randomized study comparing carfilzomib, dexamethasone and daratumumab (KdD) vs carfilzomib and dexamethasone (Kd) in relapsed or refractory multiple myeloma (RRMM). Patients treated with KdD showed a reduced risk of progression or death and achieved deeper responses when compared to Kd-treated patients. Overall, KdD was associated with a favorable benefit-risk profile and represents an efficacious new regimen for RRMM. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
